Cigna’s first-quarter results surpassed Wall Street’s revenue and non-GAAP profit expectations, with management highlighting strong performance from the company’s specialty pharmacy and pharmacy benefit services platforms. CEO David Cordani attributed momentum to the combined strengths of the EverNorth and Cigna Healthcare businesses, noting in particular the expansion of high-touch specialty services and broader adoption of biosimilar drugs. Cordani emphasized, “We delivered this performance in a dynamic environment with forces of change going beyond tariffs and trade, significant geopolitical, and evolving social impacts.” Management also pointed to disciplined capital deployment, including the completion of the Medicare business divestiture, as a contributor to the quarter’s results.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.
Abbott Laboratories has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 17.8% and now trades at $133.43. This performance may have investors wondering how to approach the situation.
The draft Senate bill introduces stricter work requirements and funding curbs for Medicaid, while shelving proposed Medicare cuts that could have impacted major insurers.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Cigna (NYSE:CI) and its peers.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Cigna trades at $313 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 7.3% while the S&P 500 is down 2.5%. This may have investors wondering how to approach the situation.
The Ninth Circuit affirmed a decision denying the FTC's application to block Microsoft's acquisition of Activision Blizzard. The FTC dropped the case and Trump's personnel changes may impact future tech regulation and antitrust enforcement.
The Federal Trade Commission voted 3-0 Thursday to dismiss a lawsuit against PepsiCo Inc. that accused the beverage giant of offering preferential pricing to major retailers, marking a significant shift from Biden-era corporate scrutiny under the new Trump administration.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications such as Wegovy and Zepbound, a move that could significantly disrupt pricing in the weight loss drug market.
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
US healthcare stocks came under pressure after CMS said it would expand Medicare Advantage audits and partner with the HHS Inspector General to recover past overpayments.
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
